A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

November 12, 2021

Study Completion Date

March 18, 2022

Conditions

Elevated Serum Lipoprotein(a)

Interventions

DRUG

Olpasiran

Subcutaneous injection

Trial Locations (1)

Queen Mary Hospital, Hong Kong